Company news

Share this article:
Mylan Pharmaceuticals has entered into a deal with Novartis to market letrozole 2.5 mg tablets, a generic version of Novartis's breast cancer product Femara. Letrozole tablets posted U.S. sales of approximately $470 million for the 12 month period ending Sept. 30, 2008, according to a Mylan statement. 
 
Titan Pharmaceuticals, a manufacturer focused primarily on the development and commercialization of Probuphine, a treatment for opiate addiction, has reduced its workforce by 40%. Further staff reductions are anticipated in the next several weeks, a company statement said. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.